$RXRX

$RXRX reported Q3 2026 EPS of -$0.22, beating the -$0.23 estimate by 4.3%. Revenue of $18.6M beat the $14.0M estimate by 32.2%…

$RXRX - Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sa…

$RXRX - New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Lar…

$RXRX - Recursion Appoints Fred Hassan as Chair of the Board…

$RXRX - Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3…

$RXRX - Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration…

$RXRX - Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock…

$RXRX - Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone…

$RXRX Cathie Wood's ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today…

$RXRX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RXRX : $2.97 Sector: Healthcare | YTD: 🔽 -29.45% The SEC disclo…

$RXRX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RXRX : $3.01 Sector: Healthcare | YTD: 🔽 -28.50% The SEC disclo…

$RXRX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RXRX : $2.99 Sector: Healthcare | YTD: 🔽 -28.98% The SEC disclo…